ReviewFrontiers in immunology2026
Spatial immune niches in gastric cancer immunotherapy resistance: mechanisms and translational implications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have changed the treatment landscape for gastric and gastroesophageal junction adenocarcinoma, yet durable benefit remains uneven across biomarker-defined groups. PD-L1 combined positive score, MSI/dMMR, tumor mutational burden, EBV status, HER2, and CLDN18.2 guide treatment eligibility, but they do not explain why effector immunity succeeds in one lesion and fails in another. This narrative review uses spatial immune niches as a framework for interpreting immunotherapy resistance in gastric cancer. These niches are tissue compartments in which malignant-cell states, effector-cell access, tertiary lymphoid structures, cancer-associated fibroblasts, tumor-associated macrophages, extracellular matrix, vascular function, and metastatic-site ecology jointly shape response. We synthesize evidence from clinical trials, single-cell and spatial multi-omics, multiplex immunohistochemistry and immunofluorescence, digital pathology, and translational biomarker studies. The review highlights clinically relevant niche states, including lymphoid-organized inflamed, inflamed-but-suppressed, stromal-excluded, myeloid-dominant, vascular/hypoxic, target-antigen-associated, and peritoneal metastatic niches. It further discusses how compact spatial assays could refine patient selection and support niche-matched combination strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.